Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02072161 · ClinicalTrials.gov registry record · Phase 2
Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy
A Phase 2 study, sponsored by Esperion Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 133
- Enrollment target
NCT02072161: Completed Phase 2 study, sponsored by Esperion Therapeutics.
NCT02072161 is a Phase 2 study that has completed, run by Esperion Therapeutics. The registered enrollment target is 133 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02072161, a Phase 2 study, has completed, sponsored by Esperion Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 133 participants
- Enrollment target
Study Summary
The purpose of this research study is to see how ETC-1002 is tolerated in the body and how ETC-1002 affects the levels of LDL-C (bad cholesterol) in patients receiving ongoing statin therapy.
Interventions
- DRUG Placebo
- DRUG ETC-1002
- DRUG Statin Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
What the finished NCT02072161 record still lists
NCT02072161 is an interventional study that assigns participants to a tested intervention. The registered 133 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02072161 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02072161 about?
NCT02072161 is a clinical study titled "Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy". The purpose of this research study is to see how ETC-1002 is tolerated in the body and how ETC-1002 affects the levels of LDL-C (bad cholesterol) in patients receiving ongoing statin therapy.
What is the current status of trial NCT02072161?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2014-03. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02072161?
The interventions under investigation include: Placebo (DRUG), ETC-1002 (DRUG), Statin Therapy (DRUG).
Who is sponsoring clinical trial NCT02072161?
This trial is sponsored by Esperion Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02072161's enrollment target sits among peer trials
133 538th of 2000 higher than 1,462 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276870 · 133 participants · Phase 2
Orphan Indications for CD19 Redirected Autologous T Cells
- NCT04671771 · 133 participants · NA
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
- NCT05610085 · 133 participants · Phase 2
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
- NCT06206486 · 133 participants
The Gut Microbiome and Serum Metabolites As a Biological Mechanism Underlying Pain in Kidney Transplantation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia